(Q39096237)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Keita Ito

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Shiori Kuroki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Yu Sasaki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Taisuke Iwata

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Kohei Mori

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tetsuya Kuroki

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Yuta Ozawa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Masanori Tetsuka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tomoko Nakagawa

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Teruyo Hiroi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Hitomi Yamamoto

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Kenichiro Ono

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tsukimi Washizu

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Makoto Bonkobara

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

1 reference

11 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

published in

The Veterinary Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

577-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Vemurafenib: the first drug approved for BRAF-mutant cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

KIT as a therapeutic target in metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

KIT gene exon 11 mutations in canine malignant melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Somatic activation of KIT in distinct subtypes of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Masitinib is safe and effective for the treatment of canine mast cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

The IKK NF-kappa B system: a treasure trove for drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Tumor control versus adverse events with targeted anticancer therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Mechanisms of proteasome inhibitor action and resistance in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Oral malignant melanoma - the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

A comparative review of melanocytic neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2013.08.003

10.1016/J.TVJL.2013.08.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035468%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference